Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.55 |
| ▸ | PKM | P14618 | 2/20 | 0.55 |
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.55 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.55 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.55 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.55 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.51 |
| ▸ | NPC1 | O15118 | 4/20 | 0.51 |
| ▸ | RAB9A | P51151 | 4/20 | 0.51 |
| ▸ | GAA | P10253 | 3/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | PARP1 | P09874 | 1/20 | 0.50 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.50 |
| ▸ | PARP3 | Q9Y6F1 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4302959 | 0.86 | CYP2C9 (0.56) | KDM4EALDH1A1NPC1RAB9AGAA | |
| SCHEMBL16217008 | 0.85 | NPC1 (0.52) | KDM4ELMNAADORA3ALDH1A1NPC1 | |
| SCHEMBL6261500 | 0.83 | SLC9A1 (0.49) | KDM4EPKMLMNAADORA3ADORA2A | |
| Hydrochloric Acid SCHEMBL6313073 | 0.82 | SLC9A1 (0.48) | KDM4EPKMLMNAADORA3ADORA2A | |
| SCHEMBL3568441 | 0.81 | ALDH1A1 (0.54) | KDM4EPKMLMNAADORA3ADORA2A | |
| SCHEMBL6313558 | 0.81 | ALDH1A1 (0.50) | KDM4EPKMLMNAADORA3ADORA2A | |
| SCHEMBL29794622 | 0.81 | DGAT1 (0.55) | KDM4ELMNAALDH1A1NPC1RAB9A | |
| SCHEMBL17239570 | 0.81 | ALDH1A1 (0.52) | KDM4EPKMLMNAADORA3ADORA2A | |
| Hydrochloric Acid SCHEMBL6313068 | 0.80 | DGAT1 (0.49) | KDM4EPKMLMNAADORA3ADORA2A | |
| SCHEMBL13860921 | 0.80 | KMT2A (0.67) | KDM4EPKMLMNAADORA3ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021072238-A1 | FEEDER-BASED AND FEEDER-FREE STEM CELL CULTURE SYSTEMS FOR STRATIFIED EPITHELIAL STEM CELLS, AND USES RELATED THERETO | UNIVERSITY OF HOUSTON SYSTEM (US) | 2021-04-15 | — | — | WO | disclosed |
| CN-108329246-B | Pyrrolidinyl urea and pyrrolidinyl thiourea compounds as TRKA kinase inhibitors | 阵列生物制药公司 | 2021-02-26 | — | — | CN | disclosed |
| US-9796711-B2 | Substituted pyrazolo[3,4-b]pyridin-6-carboxylic acids and method of use | ABBVIE S.Á.R.L. (LU) | 2017-10-24 | — | — | US | disclosed |
| US-20170101406-A1 | SUBSTITUTED PYRAZOLO[3,4-b]PYRIDIN-6-CARBOXYLIC ACIDS AND METHOD OF USE | ABBVIE OVERSEAS S.Á.R.L. (LU) | 2017-04-13 | — | — | US | disclosed |
| EP-3140298-A1 | TROPOMYOSIN-RELATED KINASE INHIBITORS | Pfizer Inc. (US) | 2017-03-15 | — | — | EP | disclosed |
| US-9328096-B2 | Tropomyosin-related kinase inhibitors | PFIZER INC. (US) | 2016-05-03 | — | — | US | disclosed |
| WO-2015170218-A1 | TROPOMYOSIN-RELATED KINASE INHIBITORS | PFIZER INC. (US) | 2015-11-12 | — | — | WO | disclosed |
| US-20150322043-A1 | TROPOMYOSIN-RELATED KINASE INHIBITORS | PFIZER (US) | 2015-11-12 | — | — | US | disclosed |
| WO-2012158413-A2 | PYRROLIDINYL UREA AND PYRROLIDINYL THIOUREA COMPOUNDS AS TRKA KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2012-11-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170101406-A1 | SUBSTITUTED PYRAZOLO[3,4-b]PYRIDIN-6-CARBOXYLIC ACIDS AND METHOD OF USE | CFTR, CHRM3, P2RY1 | KDM4E 4749/4885PKM 1040/4885LMNA 4686/4885 |
| US-20150322043-A1 | TROPOMYOSIN-RELATED KINASE INHIBITORS | TPM3, MUSK, TPM4 | KDM4E 2614/4885PKM 892/4885LMNA 2061/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.